Literature DB >> 32095743

The First Frontier: Digital Biomarkers for Neurodegenerative Disorders.

E Ray Dorsey1,2, Spyros Papapetropoulos3,4, Mulin Xiong2, Karl Kieburtz1,2.   

Abstract

Current measures of neurodegenerative diseases are highly subjective and based on episodic visits. Consequently, drug development decisions rely on sparse, subjective data, which have led to the conduct of large-scale phase 3 trials of drugs that are likely not effective. Such failures are costly, deter future investment, and hinder the development of treatments. Given the lack of reliable physiological biomarkers, digital biomarkers may help to address current shortcomings. Objective, high-frequency data can guide critical decision-making in therapeutic development and allow for a more efficient evaluation of therapies of increasingly common disorders.
Copyright © 2017 by S. Karger AG, Basel.

Entities:  

Keywords:  Alzheimer disease; Amyotrophic lateral sclerosis; Biomarkers; Biosensing techniques; Huntington disease; Neurodegenerative diseases; Outcome assessment; Parkinson disease; Research; Smartphone; Technology; Therapeutics

Year:  2017        PMID： 32095743      PMCID： PMC7015357          DOI： 10.1159/000477383

Source DB:  PubMed          Journal:  Digit Biomark        ISSN： 2504-110X


  45 in total

Review 1.  Sleep disorders in neurodegenerative diseases.

Authors:  A Raggi; R Ferri
Journal:  Eur J Neurol       Date:  2010-11       Impact factor: 6.089

2.  Joining forces to fight neurodegenerative diseases.

Authors: 
Journal:  Lancet Neurol       Date:  2013-02       Impact factor: 44.182

3.  Daytime sleep in Parkinson's disease measured by episodes of immobility.

Authors:  K Kotschet; W Johnson; S McGregor; J Kettlewell; A Kyoong; D M O'Driscoll; A R Turton; R I Griffiths; M K Horne
Journal:  Parkinsonism Relat Disord       Date:  2014-02-24       Impact factor: 4.891

4.  A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease.

Authors: 
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

5.  Feasibility of home-based automated Parkinson's disease motor assessment.

Authors:  Thomas O Mera; Dustin A Heldman; Alberto J Espay; Megan Payne; Joseph P Giuffrida
Journal:  J Neurosci Methods       Date:  2011-09-29       Impact factor: 2.390

6.  Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

Authors:  Martin Farlow; Steven E Arnold; Christopher H van Dyck; Paul S Aisen; B Joy Snider; Anton P Porsteinsson; Stuart Friedrich; Robert A Dean; Celedon Gonzales; Gopalan Sethuraman; Ronald B DeMattos; Richard Mohs; Steven M Paul; Eric R Siemers
Journal:  Alzheimers Dement       Date:  2012-06-05       Impact factor: 21.566

7.  The validity of the GaitRite and the Functional Ambulation Performance scoring system in the analysis of Parkinson gait.

Authors:  Arthur J Nelson; Dalia Zwick; Susan Brody; Christine Doran; Lori Pulver; Gitty Rooz; Marla Sadownick; Roger Nelson; Jeffrey Rothman
Journal:  NeuroRehabilitation       Date:  2002       Impact factor: 2.138

Review 8.  What Engineering Technology Could Do for Quality of Life in Parkinson's Disease: A Review of Current Needs and Opportunities.

Authors:  Jonathan A Stamford; Peter N Schmidt; Karl E Friedl
Journal:  IEEE J Biomed Health Inform       Date:  2015-08-04       Impact factor: 5.772

9.  Automated assessment of bradykinesia and dyskinesia in Parkinson's disease.

Authors:  Robert I Griffiths; Katya Kotschet; Sian Arfon; Zheng Ming Xu; William Johnson; John Drago; Andrew Evans; Peter Kempster; Sanjay Raghav; Malcolm K Horne
Journal:  J Parkinsons Dis       Date:  2012       Impact factor: 5.568

Review 10.  A systematic review of the characteristics and validity of monitoring technologies to assess Parkinson's disease.

Authors:  Catarina Godinho; Josefa Domingos; Guilherme Cunha; Ana T Santos; Ricardo M Fernandes; Daisy Abreu; Nilza Gonçalves; Helen Matthews; Tom Isaacs; Joy Duffen; Ahmed Al-Jawad; Frank Larsen; Artur Serrano; Peter Weber; Andrea Thoms; Stefan Sollinger; Holm Graessner; Walter Maetzler; Joaquim J Ferreira
Journal:  J Neuroeng Rehabil       Date:  2016-03-12       Impact factor: 4.262
View more
  20 in total

1.  A Smartphone Application as an Exploratory Endpoint in a Phase 3 Parkinson's Disease Clinical Trial: A Pilot Study.

Authors:  Alex Page; Norman Yung; Peggy Auinger; Charles Venuto; Alistair Glidden; Eric Macklin; Larsson Omberg; Michael A Schwarzschild; E Ray Dorsey
Journal:  Digit Biomark       Date:  2022-01-10

2.  Quantifying the Benefits of Digital Biomarkers and Technology-Based Study Endpoints in Clinical Trials: Project Moneyball.

Authors:  Hiromasa Mori; Stig Johan Wiklund; Jason Yuren Zhang
Journal:  Digit Biomark       Date:  2022-06-29

3.  Digital biomarkers and sex impacts in Alzheimer's disease management - potential utility for innovative 3P medicine approach.

Authors:  Robbert L Harms; Alberto Ferrari; Irene B Meier; Julie Martinkova; Enrico Santus; Nicola Marino; Davide Cirillo; Simona Mellino; Silvina Catuara Solarz; Ioannis Tarnanas; Cassandra Szoeke; Jakub Hort; Alfonso Valencia; Maria Teresa Ferretti; Azizi Seixas; Antonella Santuccione Chadha
Journal:  EPMA J       Date:  2022-06-06       Impact factor: 8.836

4.  A Remote Digital Monitoring Platform to Assess Cognitive and Motor Symptoms in Huntington Disease: Cross-sectional Validation Study.

Authors:  Florian Lipsmeier; Cedric Simillion; Atieh Bamdadian; Rosanna Tortelli; Lauren M Byrne; Yan-Ping Zhang; Detlef Wolf; Anne V Smith; Christian Czech; Christian Gossens; Patrick Weydt; Scott A Schobel; Filipe B Rodrigues; Edward J Wild; Michael Lindemann
Journal:  J Med Internet Res       Date:  2022-06-28       Impact factor: 7.076

Review 5.  Digital Biomarkers in Psychiatric Research: Data Protection Qualifications in a Complex Ecosystem.

Authors:  Andrea Parziale; Deborah Mascalzoni
Journal:  Front Psychiatry       Date:  2022-06-09       Impact factor: 5.435

6.  Detecting Mild Cognitive Impairment via Digital Biomarkers of Cognitive Performance Found in Klondike Solitaire: A Machine-Learning Study.

Authors:  Karsten Gielis; Marie-Elena Vanden Abeele; Katrien Verbert; Jos Tournoy; Maarten De Vos; Vero Vanden Abeele
Journal:  Digit Biomark       Date:  2021-02-19

Review 7.  Characteristics and Applications of Technology-Aided Hand Functional Assessment: A Systematic Review.

Authors:  Ciro Mennella; Susanna Alloisio; Antonio Novellino; Federica Viti
Journal:  Sensors (Basel)       Date:  2021-12-28       Impact factor: 3.576

Review 8.  Translational precision medicine: an industry perspective.

Authors:  Dominik Hartl; Valeria de Luca; Anna Kostikova; Jason Laramie; Scott Kennedy; Enrico Ferrero; Richard Siegel; Martin Fink; Sohail Ahmed; John Millholland; Alexander Schuhmacher; Markus Hinder; Luca Piali; Adrian Roth
Journal:  J Transl Med       Date:  2021-06-05       Impact factor: 5.531

Review 9.  Walking-related digital mobility outcomes as clinical trial endpoint measures: protocol for a scoping review.

Authors:  Ashley Marie Polhemus; Ronny Bergquist; Magda Bosch de Basea; Gavin Brittain; Sara Catherine Buttery; Nikolaos Chynkiamis; Gloria Dalla Costa; Laura Delgado Ortiz; Heleen Demeyer; Kirsten Emmert; Judith Garcia Aymerich; Heiko Gassner; Clint Hansen; Nicholas Hopkinson; Jochen Klucken; Felix Kluge; Sarah Koch; Letizia Leocani; Walter Maetzler; M Encarna Micó-Amigo; A Stefanie Mikolaizak; Paolo Piraino; Francesca Salis; Christian Schlenstedt; Lars Schwickert; Kirsty Scott; Basil Sharrack; Kristin Taraldsen; Thierry Troosters; Beatrix Vereijken; Ioannis Vogiatzis; Alison Yarnall; Claudia Mazza; Clemens Becker; Lynn Rochester; Milo Alan Puhan; Anja Frei
Journal:  BMJ Open       Date:  2020-07-19       Impact factor: 2.692

Review 10.  Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective.

Authors:  Diane Stephenson; Reham Badawy; Soania Mathur; Maria Tome; Lynn Rochester
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.